RxDoctor Payments Data

Tara Rheubottom, PA

Medical · Baton Rouge, LANPI 1134118466

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 50.6% of the total. 2025 is the largest year on record at $924, 4.1 times the $225 reported in 2021.

$3,570in general payments, 2019–2025

Across 194 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$506
  • Pfizer$431
  • Sanofi$201
  • UCB, Inc.$171
  • LEO Pharma Inc.$139
  • plus $314 from 8 others

What the payments were for

  • Food & beverage$3,570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,570 in reported general payments places this provider in the 80th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$29,234
Medicare patients
140
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab14$61,767
Dupixent PenDupilumab16$60,702
OpzeluraRuxolitinib Phosphate18$34,596
Clobetasol Propionate121$4,329
Tacrolimus38$3,795
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc92$3,507
Triamcinolone Acetonide153$2,552
Fluocinolone AcetonideFluocinolone/Shower Cap27$2,320
Clindamycin Phosphate91$2,284
Tretinoin46$2,108
Minoxidil190$1,676
Doxycycline Monohydrate49$1,485
Ammonium Lactate54$1,246
Ketoconazole80$1,151
Mupirocin142$1,079

Paid to pharmacies, not to this prescriber.

Other medical in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →